Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Demographic"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database
Jae Seung Lee, In Rae Cho, Hye Won Lee, Mi Young Jeon, Tae Seop Lim, Oidov Baatarkhuu, Do Young Kim, Kwang-Hyub Han, Jun Yong Park
Cancer Res Treat. 2019;51(4):1347-1356.   Published online February 12, 2019
DOI: https://doi.org/10.4143/crt.2018.477
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Conditional survival estimates (CSE) can provide additional useful prognostic information on the period of survival after diagnosis, which helps in counseling patients with cancer on their individual prognoses. This study aimed to analyze conditional survival (CS) for hepatocellular carcinoma (HCC) using a Korean national registry.
Materials and Methods
Patients with HCC, registered in the Korean cancer registry database, were retrospectively reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year CS at X year or month after diagnosis were calculated as CS1=OS(X+1)/OS(X). CS calculations were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage 0, A, and B underwent subgroup analysis using initial treatment methods.
Results
A total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and 2,721 who were diagnosed from January 2011 to December 2012, were separately reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%, 88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%, respectively. The subgroup analysis showed the same tendency towards increased CSE in the advanced stages.
Conclusion
Overall, the CS improved with each additional year after diagnosis in both groups. CSE may therefore provide a more accurate prognosis and hopeful message to patients who are surviving with or after treatment.

Citations

Citations to this article as recorded by  
  • Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study
    Jacob Cumming, Nick Scott, Jessica Howell, Joan Ericka Flores, Damian Pavlyshyn, Margaret E. Hellard, Leon Shin-han Winata, Marno Ryan, Tom Sutherland, Alexander J. Thompson, Joseph S. Doyle, Rachel Sacks-Davis
    Cancers.2024; 16(15): 2745.     CrossRef
  • Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study
    Jie Kong, Tingfeng Huang, Jianxi Zhang, Shichuan Tang, Hongzhi Liu, Jingfeng Liu, Yongyi Zeng
    HPB.2023; 25(2): 179.     CrossRef
  • Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
    Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Early diagnosis and prognosis of hepatocellular carcinoma based on a ceRNA array
    Li-xin Wang, Ao-ran Kong, Hui Dong
    Oncologie.2023; 25(3): 245.     CrossRef
  • Conditional survival probability of distant-metastatic hepatocellular carcinoma: A population-based study
    Yong-Ping Yang, Cheng-Jun Guo, Zhao-Xuan Gu, Jun-Jie Hua, Jia-Xuan Zhang, Jian Shi
    World Journal of Gastrointestinal Oncology.2023; 15(11): 1874.     CrossRef
  • Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
    Hye Won Lee, Kyung Joo Cho, Jun Yong Park
    Immune Network.2020;[Epub]     CrossRef
  • Dynamic evaluation of conditional survival in patients with oral squamous cell carcinoma after surgical resection: A large-scale prospective study
    Lingjun Yan, Fa Chen, Lin Chen, Jing Lin, Qing Chen, Xiaodan Bao, Yu Qiu, Lisong Lin, Xiaoyan Zheng, Lizhen Pan, Jing Wang, Zhijian Hu, Fengqiong Liu, Baochang He, Bin Shi
    Oral Oncology.2020; 104: 104639.     CrossRef
  • Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
    Jaewoong Kim, Jin Won Chang, Jun Yong Park
    Journal of Liver Cancer.2020; 20(1): 72.     CrossRef
  • Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park
    Cancers.2019; 11(4): 509.     CrossRef
  • 7,371 View
  • 140 Download
  • 8 Web of Science
  • 9 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP